DK2683643T3 - Prostatacancercellelinjer, gensignaturer og anvendelser deraf - Google Patents
Prostatacancercellelinjer, gensignaturer og anvendelser deraf Download PDFInfo
- Publication number
- DK2683643T3 DK2683643T3 DK12755544.9T DK12755544T DK2683643T3 DK 2683643 T3 DK2683643 T3 DK 2683643T3 DK 12755544 T DK12755544 T DK 12755544T DK 2683643 T3 DK2683643 T3 DK 2683643T3
- Authority
- DK
- Denmark
- Prior art keywords
- prostatacancer
- signatures
- applications
- cell lines
- lines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G01N33/575—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161450767P | 2011-03-09 | 2011-03-09 | |
| PCT/US2012/028546 WO2012122499A2 (en) | 2011-03-09 | 2012-03-09 | Prostate cancer cell lines, gene signatures and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2683643T3 true DK2683643T3 (da) | 2019-08-12 |
Family
ID=46798838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12755544.9T DK2683643T3 (da) | 2011-03-09 | 2012-03-09 | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
| DK19173075.3T DK3597761T3 (da) | 2011-03-09 | 2012-03-09 | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19173075.3T DK3597761T3 (da) | 2011-03-09 | 2012-03-09 | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10952415B2 (da) |
| EP (2) | EP2683643B1 (da) |
| JP (2) | JP2014518610A (da) |
| CN (1) | CN104169425A (da) |
| AU (1) | AU2012225232B2 (da) |
| BR (1) | BR112013023050A8 (da) |
| CA (1) | CA2829219C (da) |
| DK (2) | DK2683643T3 (da) |
| ES (2) | ES2740399T3 (da) |
| MX (1) | MX2013010330A (da) |
| WO (1) | WO2012122499A2 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2683643T3 (da) | 2011-03-09 | 2019-08-12 | Richard G Pestell | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
| HK1209673A1 (en) * | 2012-05-14 | 2016-04-08 | Prostagene Llc | Using modulators of ccr5 for treating cancer |
| CN103881975B (zh) * | 2014-04-04 | 2015-10-21 | 武汉大学 | 人前列腺癌细胞及其原代分离培养和传代培养方法与用途 |
| FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| WO2016145294A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| US20180259533A1 (en) * | 2015-09-09 | 2018-09-13 | Somalogic, Inc. | Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles |
| CN109477146B (zh) | 2016-05-10 | 2023-09-19 | 国立大学法人东京医科齿科大学 | 炎症促进因子表达抑制剂、其有效成分的筛选方法、对该方法有用的表达盒、诊断药和诊断方法 |
| AU2018364001A1 (en) | 2017-11-09 | 2020-06-25 | National University Corporation Tokyo Medical And Dental University | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
| US10721069B2 (en) | 2018-08-18 | 2020-07-21 | Eygs Llp | Methods and systems for enhancing privacy and efficiency on distributed ledger-based networks |
| US11316691B2 (en) | 2019-04-15 | 2022-04-26 | Eygs Llp | Methods and systems for enhancing network privacy of multiple party documents on distributed ledger-based networks |
| US11206138B2 (en) * | 2019-05-02 | 2021-12-21 | Ernst & Young U.S. Llp | Biosignature-based tokenization of assets in a blockchain |
| US11232439B2 (en) | 2019-08-09 | 2022-01-25 | Eygs Llp | Methods and systems for preventing transaction tracing on distributed ledger-based networks |
| EP4062585B1 (en) | 2019-11-20 | 2025-10-29 | Eygs LLP | Systems, apparatus and methods for identifying and securely storing distinguishing characteristics in a distributed ledger within a distributed ledger-based network based on fungible and non-fungible tokens |
| EP4136600A1 (en) | 2020-04-15 | 2023-02-22 | Eygs LLP | Intelligent assertion tokens for authenticating and controlling network communications using a distributed ledger |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11402391B2 (en) | 2020-12-21 | 2022-08-02 | Incelldx, Inc. | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| MX9702307A (es) | 1994-09-29 | 1998-04-30 | Novartis Ag | Pirrolo (2,3-d)pirimidinas y su uso. |
| US20040151719A1 (en) | 1995-06-06 | 2004-08-05 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| BR9611157A (pt) | 1995-11-01 | 1999-03-30 | Novartis Ag | Derivados de purina e processos para sua preparação |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| US6689765B2 (en) | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| US7825121B2 (en) | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| MXPA02007730A (es) | 2000-02-09 | 2002-10-11 | Human Genome Sciences Inc | Receptor de quimiocina de proteina g humana (ccr5) hdgnr10. |
| US6667314B2 (en) | 2000-05-26 | 2003-12-23 | Pfizer, Inc. | Tropane derivatives useful in therapy |
| DE10034109C1 (de) | 2000-07-13 | 2001-09-06 | Juergen W Mueller | Verfahren zur Verknüpfung geographischer und kommerzieller Daten sowie deren Bereitstellung |
| CA2437811A1 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
| US20020182624A1 (en) * | 2001-02-28 | 2002-12-05 | Eos Biotechnology, Inc. | Chemokine receptors and disease |
| GB0108876D0 (en) | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| WO2004054616A1 (ja) | 2002-12-13 | 2004-07-01 | Ono Pharmaceutical Co., Ltd. | ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト |
| WO2004098638A1 (ja) | 2003-05-06 | 2004-11-18 | Ono Pharmaceutical Co., Ltd. | エフェクター細胞機能阻害剤 |
| CA2594602A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Limited | 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors |
| WO2006121991A2 (en) | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
| WO2007098010A2 (en) | 2006-02-17 | 2007-08-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Improved low molecular weight myc-max inhibitors |
| MX2008011414A (es) | 2006-03-10 | 2008-09-22 | Ono Pharmaceutical Co | Derivado heterociclico nitrogenado y agente farmaceutico que comprende el derivado como ingrediente activo. |
| JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| DK2683643T3 (da) | 2011-03-09 | 2019-08-12 | Richard G Pestell | Prostatacancercellelinjer, gensignaturer og anvendelser deraf |
| US9665874B2 (en) | 2012-03-13 | 2017-05-30 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2012
- 2012-03-09 DK DK12755544.9T patent/DK2683643T3/da active
- 2012-03-09 CA CA2829219A patent/CA2829219C/en active Active
- 2012-03-09 US US14/003,384 patent/US10952415B2/en active Active
- 2012-03-09 JP JP2013557917A patent/JP2014518610A/ja active Pending
- 2012-03-09 ES ES12755544T patent/ES2740399T3/es active Active
- 2012-03-09 ES ES19173075T patent/ES3034910T3/es active Active
- 2012-03-09 DK DK19173075.3T patent/DK3597761T3/da active
- 2012-03-09 EP EP12755544.9A patent/EP2683643B1/en active Active
- 2012-03-09 WO PCT/US2012/028546 patent/WO2012122499A2/en not_active Ceased
- 2012-03-09 BR BR112013023050A patent/BR112013023050A8/pt not_active Application Discontinuation
- 2012-03-09 MX MX2013010330A patent/MX2013010330A/es unknown
- 2012-03-09 EP EP19173075.3A patent/EP3597761B1/en active Active
- 2012-03-09 CN CN201280020337.8A patent/CN104169425A/zh active Pending
- 2012-03-09 AU AU2012225232A patent/AU2012225232B2/en active Active
-
2016
- 2016-11-10 JP JP2016219554A patent/JP2017078070A/ja active Pending
-
2021
- 2021-02-04 US US17/167,578 patent/US20240224960A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2829219A1 (en) | 2012-09-13 |
| CN104169425A (zh) | 2014-11-26 |
| WO2012122499A3 (en) | 2014-04-17 |
| JP2017078070A (ja) | 2017-04-27 |
| DK3597761T3 (da) | 2025-08-18 |
| ES3034910T3 (en) | 2025-08-26 |
| JP2014518610A (ja) | 2014-08-07 |
| EP3597761A1 (en) | 2020-01-22 |
| BR112013023050A8 (pt) | 2018-09-25 |
| ES2740399T3 (es) | 2020-02-05 |
| WO2012122499A2 (en) | 2012-09-13 |
| EP2683643A2 (en) | 2014-01-15 |
| EP2683643A4 (en) | 2015-04-29 |
| AU2012225232B2 (en) | 2016-05-12 |
| US20140109245A1 (en) | 2014-04-17 |
| MX2013010330A (es) | 2014-11-26 |
| EP3597761B1 (en) | 2025-05-07 |
| BR112013023050A2 (pt) | 2016-12-06 |
| US10952415B2 (en) | 2021-03-23 |
| EP2683643B1 (en) | 2019-05-08 |
| CA2829219C (en) | 2021-03-16 |
| US20240224960A1 (en) | 2024-07-11 |
| AU2012225232A1 (en) | 2013-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2683643T3 (da) | Prostatacancercellelinjer, gensignaturer og anvendelser deraf | |
| DK2768958T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3329919T3 (da) | Acc-inhibitorer og anvendelser deraf | |
| DK3346008T3 (da) | Rekombinante mikroorganismer og anvendelser deraf | |
| PL2785359T3 (pl) | Mezenchymalne komórki zrębowe i związane z nimi zastosowania | |
| DK2855736T3 (da) | Elektrolysator og energisystem | |
| DK2850202T3 (da) | Fremgangsmåder og grupper | |
| DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
| DK3339323T3 (da) | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf | |
| DK2794654T3 (da) | Anti-phf-tau-antistoffer og deres anvendelser | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| EP2664017A4 (en) | STACK OF FLOW CELLS | |
| DK2729179T3 (da) | Makromolekyler | |
| DK2912165T3 (da) | Nyrecellepopulationer og anvendelser deraf | |
| BR112014006747A2 (pt) | pilha de célula de combustível, e, célula de combustível | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| DK2906608T3 (da) | Polyanilin-membraner, anvendelser og fremgangsmåder dertil | |
| IT1398984B1 (it) | Dispositivo blocco-porta perfezionato. | |
| EP2683139A4 (en) | PORTABLE DEVICE | |
| EP2608785A4 (en) | LIPOMA CYCLES AND ITS USES | |
| EP2686978A4 (en) | ENCRYPTED PV SIGNATURES | |
| DK2877736T3 (da) | Skrue, skruedel og fremgangsmåde dertil |